These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 26409798)
1. Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage. Bafaqih H; Chehab M; Almohaimeed S; Thabet F; Alhejaily A; AlShahrani M; Zolaly MA; Abdelmoneim AA; Abd ES Ann Saudi Med; 2015; 35(3):231-9. PubMed ID: 26409798 [TBL] [Abstract][Full Text] [Related]
2. Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage: A Case Series. Baker MS; Diab KJ; Carlos WG; Mathur P J Bronchology Interv Pulmonol; 2016 Jul; 23(3):255-8. PubMed ID: 27261934 [TBL] [Abstract][Full Text] [Related]
3. Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children. Park JA; Kim BJ Pediatrics; 2015 Jan; 135(1):e216-20. PubMed ID: 25548333 [TBL] [Abstract][Full Text] [Related]
4. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Heslet L; Nielsen JD; Levi M; Sengeløv H; Johansson PI Crit Care; 2006; 10(6):R177. PubMed ID: 17184515 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model. Bonhomme F; Lecompte T; Samama CM; Godier A; Fontana P Eur J Anaesthesiol; 2018 Mar; 35(3):208-214. PubMed ID: 29334511 [TBL] [Abstract][Full Text] [Related]
6. Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. Salomon O; Budnik I; Avishai E; Tamarin I; Bashari D; Dardik R; Livnat T Thromb Haemost; 2019 Dec; 119(12):1927-1932. PubMed ID: 31493780 [TBL] [Abstract][Full Text] [Related]
7. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. Rea CJ; Foley JH; Bevan DH; Sørensen B Ann Hematol; 2014 Apr; 93(4):683-92. PubMed ID: 24193375 [TBL] [Abstract][Full Text] [Related]
8. Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional Experience. Pathak V; Kuhn J; Gabriel D; Barrow J; Jennette JC; Henke DC Lung; 2015 Jun; 193(3):375-9. PubMed ID: 25802198 [TBL] [Abstract][Full Text] [Related]
9. Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report. Alabed IB Medicine (Baltimore); 2014 Sep; 93(14):e72. PubMed ID: 25255019 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary administration of activated recombinant factor VII. Grochova M; Kalnasova B; Firment J; Olejarova I; Roland R; Lazurova I Bratisl Lek Listy; 2011; 112(1):29-33. PubMed ID: 21452776 [TBL] [Abstract][Full Text] [Related]
11. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Hicks K; Peng D; Gajewski JL Bone Marrow Transplant; 2002 Dec; 30(12):975-8. PubMed ID: 12476294 [TBL] [Abstract][Full Text] [Related]
12. Nebulized tranexamic acid as a therapeutic alternative in pulmonary hemorrhage. González-Castro A; Rodriguez-Borregán JC; Chicote E; Escudero P; Ferrer D Arch Bronconeumol (Engl Ed); 2018 Aug; 54(8):442-443. PubMed ID: 29273349 [No Abstract] [Full Text] [Related]
13. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. Elinoff JM; Bagci U; Moriyama B; Dreiling JL; Foster B; Gormley NJ; Salit RB; Cai R; Sun J; Beri A; Reda DJ; Fakhrejahani F; Battiwalla M; Baird K; Cuellar-Rodriguez JM; Kang EM; Pavletic SZ; Fowler DH; John Barrett A; Lozier JN; Kleiner DE; Mollura DJ; Childs RW; Suffredini AF Biol Blood Marrow Transplant; 2014 Jul; 20(7):969-78. PubMed ID: 24657447 [TBL] [Abstract][Full Text] [Related]
15. Nebulized Tranexamic Acid as a Noninvasive Therapy for Cancer-Related Hemoptysis. Hankerson MJ; Raffetto B; Mallon WK; Shoenberger JM J Palliat Med; 2015 Dec; 18(12):1060-2. PubMed ID: 26381600 [TBL] [Abstract][Full Text] [Related]
16. Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. Nishijima DK; VanBuren J; Hewes HA; Myers SR; Stanley RM; Adelson PD; Barnhard SE; Bobinski M; Ghetti S; Holmes JF; Roberts I; Schalick WO; Tran NK; Tzimenatos LS; Michael Dean J; Kuppermann N; Trials; 2018 Oct; 19(1):593. PubMed ID: 30376893 [TBL] [Abstract][Full Text] [Related]
17. Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan. Post R; Germans MR; Coert BA; Rinkel GJE; Vandertop WP; Verbaan D Trials; 2020 Feb; 21(1):199. PubMed ID: 32070395 [TBL] [Abstract][Full Text] [Related]